Insmed to Participate at September Investor Conferences

BRIDGEWATER, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at the following investor conferences taking place in New York City:

  • Will Lewis, president and chief executive officer, will participate in an analyst-led fireside chat on Tuesday, September 13 at 3:30 PM ET at the Morgan Stanley Global Healthcare Conference.
  • Mr. Lewis will also participate in an analyst-led fireside chat on Wednesday, September 28 at 9:00 AM ET at the Leerink Partners Rare Disease Roundtable.

The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed’s earlier-stage clinical pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit www.insmed.com.

“Insmed” and “ARIKAYCE” are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Insmed Incorporated: Susan Mesco Head of Investor Relations 908-947-4326

Source:Insmed Incorporated